Regulation - GlaxoSmithKline, Pricing

Filter

Current filters:

GlaxoSmithKlinePricing

Popular Filters

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

09-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlarvemurafenib

IQWiG says added benefit of GSK’s Tafinlar not proven

IQWiG says added benefit of GSK’s Tafinlar not proven

07-01-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlar

New Zealand funding plans for Tarceva and Revolade

New Zealand funding plans for Tarceva and Revolade

09-12-2013

Following a consultation, New Zealand’s Pharmaceutical Management Agency PHARMAC said this morning…

Asia-PacificGlaxoSmithKlineHematologyNew ZealandOncologyPharmaceuticalPricingRegulationRevoladeRocheTarceva

UK’s NICE issues draft guidance on suite of ovarian cancer drugs

27-09-2013

Drugs watchdog the National Institute for Health and Care Excellence (NICE) is currently considering…

Europegemcitabine HclGlaxoSmithKlineJohnson & JohnsonLillyOncologyPharmaceuticalPricingRegulationtrabectedin

New Zealand proposals for influenza vaccines

21-08-2013

New Zealand's Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to list two…

Abbott LaboratoriesAsia-PacificFluarixGlaxoSmithKlineInfluvacPharmaceuticalPricingRegulationVaccines

Pharma giants included in China's investigation into pricing of foreign imports

05-07-2013

China's National Development and Reform Commission (NDRC) has launched an investigation into UK pharma…

Astellas PharmaBaxterBoehringer IngelheimGlaxoSmithKlineJiangsu Hengrui MedicinePharmaceuticalPricingRegulationSandozSinopharm Group

Positive NICE news for GSK's Revolade and InterMune's Esbriet

21-03-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

UK NICE agrees to reconsider decision to deny NHS access to GSK's Benlysta

07-09-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) confirmed this…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlinePharmaceuticalPricingRare diseasesRegulation

Final guidance from UK NICE on Tarceva, Tyverb, Herceptin, Zytiga and Botox

26-06-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today published…

AllerganBotoxEuropeGlaxoSmithKlineHerceptinJanssenJohnson & JohnsonNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarcevaTyverbZytiga

Germany's IQWiG finds in favor of Yervoy but not Benlysta or Fampyra

09-05-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) in the past few days issued a…

BenlystaBiogen IdecBiotechnologyBristol-Myers SquibbEuropeFampyraGlaxoSmithKlineNeurologicalOncologyPharmaceuticalPricingRare diseasesRegulationYervoy

UK NICE gives draft "No" to Benlysta, and negative final guidance for Tyverb and Herceptin

27-04-2012

There was a batch of bad news emanating from the US drugs watchdog the National Institute for Health…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlineHerceptinOncologyPharmaceuticalPricingRare diseasesRegulationRocheTyverb

New Zealand to fund new cancer drugs Tykerb and Votrient

05-03-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, says it is funding two new targeted cancer…

Asia-PacificGlaxoSmithKlineOncologyPharmaceuticalPricingRegulationTykerbVotrient

GSK boss accuses UK government of blocking new drugs to save money

27-02-2012

The chief executive of the UK’s largest pharmaceutical company, GlaxoSmithKline (LSE: GSK) has accused…

EuropeGlaxoSmithKlineMarkets & MarketingPharmaceuticalPricingRegulation

No proof of added benefit for GlaxoSmithKline’s Trobalt, says IQWiG

27-02-2012

In another warning to drugmakers trying to get approval of new drugs under Germany’s AMNOG reform…

EuropeGlaxoSmithKlineNeurologicalPharmaceuticalPricingRegulationTrobalt

Nine news Rx drugs added to Australian PBS listings

22-02-2012

Australia’s Federal Minister for Health, Tanya Plibersek, yesterday announced the listing of nine…

Asia-PacificAstraZenecaBrilintaGlaxoSmithKlinePharmaceuticalPricingRegulationZinnat

NICE views breast cancer drugs from GSK and Roche too expensive

14-02-2012

The UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft…

EuropeGlaxoSmithKlineHerceptinOncologyPharmaceuticalPricingRegulationRocheTyverb

Back to top